Sustained Response at 2 Years Reported for Deucravacitinib Sustained Response at 2 Years Reported for Deucravacitinib

Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, was approved September 9 by the FDA for treating adults with moderate to severe plaque psoriasis.MDedge News
Source: Medscape Rheumatology Headlines - Category: Rheumatology Tags: Dermatology News Source Type: news